Huntsman Cancer Institute Receives NIH Grant for Clinical Trial of Curacyte's PHP

16-Sep-2005

Curacyte AG and its wholly-owned subsidiary, Apex Bioscience, Inc. have announced that the Huntsman Cancer Institute (HCI) Multidisciplinary melanoma Translational Research Program has received notice of funding by the NIH for National Institutes of Health R21 Quick Trial Award - Clinical trial of PHP with high-dose interleukin-2 (IL-2),. This study is designed to test Curacyte's experimental drug, PHP, in patients receiving melanoma and kidney cancer treatment with IL-2. Laboratory studies at the HCI of the mechanism of IL-2 side effects identified this drug as a promising means of counteracting low blood pressure and "vascular leak syndrome" that currently limit IL-2-based cancer treatment.

Curacyte's PHP is a scavenger of nitric oxide (NO), the main causative agent responsible for vasodilation and hypotension in distributive shock. PHP has been demonstrated to reverse the vasodilation and resolve the hypotension associated with distributive shock. PHP has completed Phase II clinical studies in distributive shock and is entering a Phase III study. Additional clinical studies of PHP in patients with cardiogenic shock are also planned.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances